Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.
Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential role of idecabtagene vicleucel (ide-cel; BB2121) as treatment of patients with multiple myeloma.
Ide-cel is a a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy. The original data from the phase 2 KarMMA study (NCT03361748) demonstrated a 73% overall response rate, and the rate was even higher in the 450 dose, which will be the dose moving forward. The progression-free survival was approximately 1 year, so physicians know this therapy works, especially in this heavily pretreated patient population.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More